GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Net Income Including Noncontrolling Interests

MYND Life Sciences (XCNQ:MYND) Net Income Including Noncontrolling Interests : C$-0.54 Mil (TTM As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

MYND Life Sciences's Net Income Including Noncontrolling Interests for the three months ended in Jul. 2024 was C$-0.38 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jul. 2024 was C$-0.54 Mil.

MYND Life Sciences Net Income Including Noncontrolling Interests Historical Data

The historical data trend for MYND Life Sciences's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences Net Income Including Noncontrolling Interests Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
Net Income Including Noncontrolling Interests
-4.37 -3.57 -1.52

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 0.47 -0.37 -0.26 -0.38

MYND Life Sciences Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MYND Life Sciences Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

MYND Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XCNQ:NURL TSXV:MRVL XCNQ:AGN XCNQ:RIZE XCNQ:MOOD XCNQ:HEAL XCNQ:LOBE TSX:APLI TSXV:XRTX XCNQ:ENBI VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
MYNDF:USA
Address
105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2
Website
https://www.myndsciences.com
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.